Catalyst Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.catalystpharma.com

Earnings Score
Moat Score

Market Cap $2.57B
PE 18
Debt $NaN
Cash $442.33M
EV $NaN
FCF $224.02M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$142.80M
EBIT	$188.79M
ROE	22%
ROA	24%
FCF	$224.02M
Equity	$660.94M
Growth Stability	100%
PE	18.02
PEG	1.06
PB	3.89
P/FCF	11.49
P/S	5.59
Price/Cash	0.17
Net Margins	31%
Gross Margins	86%
Op. Margins	41%
Earnings CAGR	7%
Sales Growth YoY	25%
Sales Growth QoQ	5%
Sales CAGR	29%
FCF CAGR	5%
Equity CAGR	33%
Earnings Stability	0.13
Earnings Growth YoY	-243%

Earnings Growth QoQ	8%
Earnings CAGR 5Y	17%
Sales CAGR 5Y	41%
FCF CAGR 5Y	35%
Equity CAGR 5Y	46%
Earnings CAGR 3Y	61%
Sales CAGR 3Y	61%
FCF CAGR 3Y	55%
Equity CAGR 3Y	53%
Market Cap	$2.57B
Revenue	$460.48M
Assets	$772.01M
Cash	$442.33M
Shares Outstanding	117.98M
Earnings Score	8%
Moat Score	97%
Working Capital	433.6M
Current Ratio	5.11
Gross Profit	$397.47M
Shares Growth 3y	6%
Equity Growth QoQ	9%
Equity Growth YoY	90%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

SEC Filings

Direct access to Catalyst Pharmaceuticals, Inc. (CPRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Catalyst Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Catalyst Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 7%

Stability 13%

loading chart...

Catalyst Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Catalyst Pharmaceuticals, Inc..

Years

Calculation mode

= $3.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$224M	$235M	$246M	$257M	$270M	$283M	$296M	$310M	$325M	$340M	$356M	$3.6B
DCF		$213M	$203M	$193M	$184M	$175M	$167M	$159M	$151M	$144M	$137M	$1.4B
Value	$3.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-7K%	31%	63%	28%	39%	18%	31%
ROA	-	-34%	-43%	-22%	-56%	30%	22%	22%	28%	20%	24%
ROE	-	-36%	-46%	-23%	-67%	36%	44%	19%	28%	18%	22%

Good Net Margins (30.85%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	100%	100%	100%	100%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (100%)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	20K%	16%	18%	52%	86%	41%
Earnings YoY growth	-	30%	-11%	2%	85%	-194%	135%	-47%	110%	-14%	17%
Equity YoY growth	-	57%	-29%	106%	-37%	73%	94%	22%	45%	29%	46%
FCF YoY growth	-	39%	0%	-	-	-234%	30%	32%	95%	24%	35%